Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CCX 140

Next Previous
Drug Profile

CCX 140

Alternative Names: CCX-140B; CCX140

Latest Information Update: 16 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Vifor
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Focal segmental glomerulosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis
  • Research Kidney disorders
  • No development reported Type 2 diabetes mellitus
  • Discontinued Multiple sclerosis; Vascular restenosis

Most Recent Events

  • 10 Oct 2018 Chemical structure information added
  • 01 Oct 2018 ChemoCentryx initiates enrolment in the phase II LUMINA 2 trial for Focal Segmental Glomerulosclerosis in USA (NCT03703908)
  • 12 Sep 2018 CCX 140 receives Orphan Drug status for Focal segmental glomerulosclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top